Source: International Congress 2018 – Pleural diseases and pneumonia: what's new ?
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kharitonov (Saint-Petersburg, Russian Federation), A. Nikolayev (Saint-Petersburg, Russian Federation), M. Zhurkin (Saint-Petersburg, Russian Federation), V. Ivanov (Saint-Petersburg, Russian Federation), Y. Rudakov (Saint-Petersburg, Russian Federation). The use of antiviral drug Ribavirin in cases of viral-bacterial community acquired pneumonia. 1971

Member's Comments

No comment yet.

Related content which might interest you: Switching of antimicrobial agents in the therapy of community acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Using roncoleukine in basic therapy of patients with community acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 443s Year: 2002 The efficiency of levofloxacin in the therapy of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 5s Year: 2006 The efficacy of antiviral therapy of acute respiratory infections in paediatric practice Source: International Congress 2017 – New insights into paediatric respiratory infections Year: 2017 The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006 Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia? Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Cytokine-based prediction of aetiology in community acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017 Previous antibacterial therapy and drug-resistance among pathogens in ICU patients with nosocomial pneumonia Source: Eur Respir J 2001; 18: Suppl. 33, 405s Year: 2001 The usage of laferon in treatment of patients with community acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007 Investigating trends in antituberculosis (anti-TB) drug resistance among treated patients of a university respiratory infections unit in Greece Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Current treatments for respiratory infections in children Source: Annual Congress 2005 - PG5 - Paediatrics: respiratory infections in children Year: 2005 Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART Source: Breathe 2008; 5: 274 Year: 2009 Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Hospital-acquired pneumonia in patients receiving immunosuppressive therapy Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009